Initial management of epilepsy

New England Journal of Medicine

Volumn 359, Issue 2, 2008, Pages 166-176

  French, Jacqueline A ^a,c   Pedley, Timothy A ^b  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Och Spine at New York Presbyterian Hospitals   (United States)

^c NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; DEPAKOTE ER; ETIRACETAM; GABAPENTIN; KEPPRA IV; LAMICTAL XR; LAMOTRIGINE; OXCARBAZEPINE; PHENOBARBITAL; PHENYTEK; PHENYTOIN; PREGABALIN; TIAGABINE; TOPIRAMATE; VALPROATE SEMISODIUM; VALPROIC ACID; ZONISAMIDE;

ADULT; AGRANULOCYTOSIS; ANOREXIA; APLASTIC ANEMIA; ARTICLE; ATAXIA; BLOOD DYSCRASIA; BLURRED VISION; CASE REPORT; CLINICAL FEATURE; CLINICAL PRACTICE; CLOSED ANGLE GLAUCOMA; CONFUSION; DEPRESSION; DIPLOPIA; DIZZINESS; DROWSINESS; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG WITHDRAWAL; EDEMA; EPILEPSY; FATIGUE; FEMALE; HAIR LOSS; HEADACHE; HEAT STROKE; HUMAN; HYPERACTIVITY; HYPERAMONEMIA; HYPERSENSITIVITY; HYPONATREMIA; INSOMNIA; IRRITABILITY; LEUKOPENIA; LIVER FAILURE; LOADING DRUG DOSE; LUPUS LIKE SYNDROME; MENTAL CONCENTRATION; METABOLIC ACIDOSIS; MULTIPLE ORGAN FAILURE; MYALGIA; NAUSEA; NEPHROLITHIASIS; NERVE BLOCK; NERVOUSNESS; NEUROLOGIC EXAMINATION; OLIGOHYDROSIS; PANCREATITIS; PARESTHESIA; PRIORITY JOURNAL; PSEUDOLYMPHOMA; RASH; SEDATION; SEIZURE; SIDE EFFECT; SOMNOLENCE; SPEECH DISORDER; STEVENS JOHNSON SYNDROME; THROMBOCYTOPENIA; TOXIC EPIDERMAL NECROLYSIS; TREMOR; VOMITING; WEAKNESS; WEIGHT GAIN; WEIGHT REDUCTION; DIFFERENTIAL DIAGNOSIS; DRUG INTERACTION; PRACTICE GUIDELINE; PSYCHOLOGICAL ASPECT; REVIEW;

ADULT; ANTICONVULSANTS; DEPRESSIVE DISORDER; DIAGNOSIS, DIFFERENTIAL; DRUG INTERACTIONS; EPILEPSY; FEMALE; HUMANS; NEUROLOGIC EXAMINATION; PRACTICE GUIDELINES AS TOPIC;

EID: 46949111707     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMcp0801738     Document Type: Article

References (57)

1. Hauser WA, Annegers JF, Kurland LT. Incidence of epilepsy and unprovoked seizures in Rochester, Minnesota: 1935-1984. Epilepsia 1993;34:453-68.
2. Idem. Prevalence of epilepsy in Rochester, Minnesota: 1940-1980. Epilepsia 1991;32:429-45.
3. Annegers JF, Dubinsky S, Coan SP, Newmark ME, Roht L. The incidence of epilepsy and unprovoked seizures in multiethnic, urban health maintenance organizations. Epilepsia 1999;40:502-6.
4. Banerjee PN, Hauser WA. Incidence and prevalence. In: Engel J Jr, Pedley TA, eds. Epilepsy: a comprehensive textbook. 2nd ed. Baltimore: Wolters Kluwer/Lippincott Williams & Wilkins, 2008:45-56.
5. Cloyd J, Hauser W, Towne A, et al. Epidemiological and medical aspects of epilepsy in the elderly. Epilepsy Res 2006; 68:Suppl 1:S39-S48.
6. Annegers JF, Hauser WA, Lee JR, Rocca WA. Incidence of acute symptomatic seizures in Rochester, Minnesota, 1935-1984. Epilepsia 1995;36:327-33.
7. Krumholz A, Wiebe S, Gronseth G, et al. Evaluating an apparent unprovoked first seizure in adults (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology 2007;69:1996-2007.
8. Fisch B, So E. Activation methods. In: Ebersole JS, Pedley TA, eds. Current practice of clinical electroencephalography. 3rd ed. Philadelphia: Lippincott Williams & Wilkins, 2003:262-4.
9. Bronen RA, Fulbright RK, Spencer DD, et al. Refractory epilepsy: comparison of MR imaging, CT, and histopathologic findings in 117 patients. Radiology 1996;201:97-105.
10. Harden CL, Huff JS, Schwartz TH, et al. Reassessment: neuroimaging in the emergency patient presenting with seizure (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2007;69:1772-80.
11. Epilepsy Foundation. Driver information by state. (Accessed June 12, 2008, at http://www.epilepsyfoundation.org/living/ wellness/transportation/ drivinglaws.cfm.)
12. Mendez MF, Cummings JL, Benson DF. Depression in epilepsy: significance and phenomenology. Arch Neurol 1986; 43:766-70.
13. Indaco A, Carrieri PB, Nappi C, Gentile S, Striano S. Interictal depression in epilepsy. Epilepsy Res 1992;12:45-50.
14. Christensen J, Vestergaard M, Mortensen PB, Sidenius P, Agerbo E. Epilepsy and risk of suicide: a population-based case-control study. Lancet Neurol 2007;6:693-8.
15. Kanner AM, Nieto JC. Depressive disorders in epilepsy. Neurology 1999;53:5 Suppl 2:S26-S32.
16. Gilliam F. Depression and epilepsy. In: Gilliam F, Kanner AM, Sheline Y, eds. Depression and brain dysfunction. New York: Taylor & Francis, 2006:173-88.
17. Gilliam FG, Barry JJ, Hermann BP, Meador KJ, Vahle V, Kanner AM. Rapid detection of major depression in epilepsy: a multicentre study. Lancet Neurol 2006; 5:399-405.
18. Epilepsy Foundation. Mood disorders and epilepsy: Neurological Disorders Depression Inventory for Epilepsy (NDDI-E) screeningtool. (Accessed June 12, 2008, at http://www.epilepsyfoundation.org/about/ related/mood/nddietool.cfm.)
19. Food and Drug Administration. Information for healthcare professionals: suicidality and antiepileptic drugs. January 31, 2008. (Accessed May 30, 2008, at http://www.fda.gov/Cder/Drug/InfoSheets/ HCP/antiepilepticsHCP.htm.)
20. Berg AT. Risk of recurrence after a first unprovoked seizure. Epilepsia 2008; 49:Suppl 1:13-8.
21. Marson A, Jacoby A, Johnson A, Kim L, Gamble C, Chadwick D. Immediate versus deferred antiepileptic drug treatment for early epilepsy and single seizures: a randomised controlled trial. Lancet 2005; 365:2007-13.
22. French JA, Kanner AM, Bautista J, et al. Efficacy and tolerability of the new antiepileptic drugs. I. Treatment of new onset epilepsy: report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology 2004;62:1252-60.
23. Perucca E, Gram L, Avanzini G, Dulac O. Antiepileptic drugs as a cause of worsening seizures. Epilepsia 1998;39:5-17.
24. Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med 2000;342:314-9.
25. Marson AG, Al-Kharusi AM, Alwaidh M, et al. The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial. Lancet 2007;369:1016-26.
26. Chung WH, Hung SI, Hong HS, et al. Medical genetics: a marker for Stevens-Johnson syndrome. Nature 2004;428:486.
27. Beydoun A. Monotherapy trials of new antiepileptic drugs. Epilepsia 1997; 38:Suppl 9:S21-S31.
28. Pack AM, Morrell MJ, Marcus R, et al. Bone mass and turnover in women with epilepsy on antiepileptic drug monotherapy. Ann Neurol 2005;57:252-7.
29. Drezner MK. Treatment of anticonvulsant drug-induced bone disease. Epilepsy Behav 2004;5:Suppl 2:S41-S47.
30. Bilo L, Meo R, Nappi C, et al. Reproductive endocrine disorders in women with primary generalized epilepsy. Epilepsia 1988;29:612-9.
31. Herzog AG, Schachter SC. Valproate and the polycystic ovarian syndrome: final thoughts. Epilepsia 2001;42:311-5.
32. Herzog AG, Coleman AE, Jacobs AR, et al. Interictal EEG discharges, reproductive hormones, and menstrual disorders in epilepsy. Ann Neurol 2003;54:625-37.
33. [Erratum, Ann Neurol 2004;55:148.]
34. Herzog AG, Fowler KM. Sexual hormones and epilepsy: threat and opportunities. Curr Opin Neurol 2005;18:167-72.
35. Isojärvi JI, Rättyä J, Myllylä VV, et al. Valproate, lamotrigine, and insulin-mediated risks in women with epilepsy. Ann Neurol 1998;43:446-51.
36. Isojärvi JI, Laatikainen TJ, Pakarinen AJ, Juntunen KT, Myllyla VV. Polycystic ovaries and hyperandrogenism in women taking valproate for epilepsy. N Engl J Med 1993;329:1383-8.
37. Betts T, Yarrow H, Dutton N, Greenhill L, Rolfe T. A study of anticonvulsant medication on ovarian function in a group of women with epilepsy who have only ever taken one anticonvulsant compared with a group of women without epilepsy. Seizure 2003;12:323-9.
38. Harden CL. Polycystic ovaries and polycystic ovary syndrome in epilepsy: evidence for neurogonadal disease. Epilepsy Curr 2005;5:142-6.
39. Pennell PB, Gidal BE, Sabers A, Gordon J, Perucca E. Pharmacology of antiepileptic drugs during pregnancy and lactation. Epilepsy Behav 2007;11:263-9.
40. Barrett C, Richens A. Epilepsy and pregnancy: report of an Epilepsy Research Foundation workshop. Epilepsy Res 2003; 52:14 7-87.
41. Duncan S. Teratogenesis of sodium valproate. Curr Opin Neurol 2007;20:175-80.
42. Adab N, Kini U, Vinten J, et al. The longer term outcome of children born to mothers with epilepsy. J Neurol Neurosurg Psychiatry 2004;75:1575-83.
43. Vinten J, Adab N, Kini U, Gorry J, Gregg J, Baker GA. Neuropsychological effects of exposure to anticonvulsant medication in utero. Neurology 2005;64:949-54.
44. Mendis GP, Gibberd FB, Hunt HA. Plasma activities of hepatic enzymes in patients on anticonvulsant therapy. Seizure 1993;2:319-23.
45. Sheth RD. Met abolic concerns associated with antiepileptic medications. Neurology 2004;63:Suppl 4:S24-S29.
46. Israni RK, Kasbekar N, Haynes K, Berns JS. Use of antiepileptic drugs in patients with kidney disease. Semin Dial 2006;19:408-16.
47. Patsalos PN, Perucca E. Clinically important drug interactions in epilepsy: interactions between antiepileptic drugs and other drugs. Lancet Neurol 2003;2:473-81.
48. Herzberg L. Carbamazepine and bradycardia. Lancet 1978;1:1097-8.
49. Nasreddine W, Beydoun A. Valproateinduced thrombocytopenia: a prospective monotherapy study. Epilepsia 2008;49: 438-45.
50. Gidal B, Spencer N, Maly M, et al. Valproate-mediated disturbances of hemostasis: relationship to dose and plasma concentration. Neurology 1994;44:1418-22.
51. Ben-Menachem E. Weight issues for people with epilepsy - a review. Epilepsia 2007;48:Suppl 9:42-5.
52. Biton V. Weight change and antiepileptic drugs: health issues and criteria for appropriate selection of an antiepileptic agent. Neurologist 2006;12:163-7.
53. Berg AT, Shinnar S. Relapse following discontinuation of antiepileptic drugs: a meta-analysis. Neurology 1994;44:601-8.
54. Patsalos PN, Berry DJ, Bourgeois BF, et al. Antiepileptic drugs-best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies. Epilepsia (in press).
55. Bialer M. Generic products of antiepileptic drugs (AEDs): is it an issue? Epilepsia 2007;48:1825-32.
56. Specchio LM, Beghi E. Should antiepileptic drugs be withdrawn in seizure-free patients? CNS Drugs 2004;18:201-12.
57. Glauser T, Ben-Menachem E, Bourgeois B, et al. ILAE treatment guidelines: evidence-based analysis of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia 2006;47:1094-120.